A$195.65 4.4 2.3%
Last Trade - 5:10am
| Market Cap | ÂŁ7.12bn |
| Enterprise Value | ÂŁ6.99bn |
| Revenue | ÂŁ748.7m |
| Position in Universe | 44th / 1843 |
| Industry | Market | |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
| Year End 30th Jun | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021E | 2022E | CAGR / Avg | |
|---|---|---|---|---|---|---|---|---|---|---|
| 925.6 | 1,131 | 1,254 | 1,364 | 1,427 | 1,321 | 1,461 | 1,698 | +7.4% | ||
| +32.9 | +31.0 | +14.0 | +8.5 | +9.1 | +16.9 | -39.2 | +35.7 | |||
|
x
|
||||||||||
| Profitability | ||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
|
%
|
||||||||||
| Cashflow | ||||||||||
| Dividends | ||||||||||
| Balance Sheet | ||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
|
m
|
||||||||||
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing % | |||
| Net Gearing % | |||
| Cash / Assets % |
| Liquidity (ttm) | ||
|---|---|---|
| Curr. Ratio | ||
| Quick Ratio | ||
| Interest Cov. | ||
| Efficiency (ttm) | ||
|---|---|---|
| Asset Turnover | ||
| Recs Turnover | ||
| Stock Turnover | ||
| Latest interim period vs. prior period | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
| 3yr Compound Annual Growth Rate | Industry | Market |
|---|---|---|
|
|
|
|
|
|
|
|
|
|
|
Revenue
Net Income
Normalised EPS
PE Ratio Range
Dividend Yield Range
|
Price Target:
( below Price)
|
31st Dec 2021
|
31st Dec 2022
|
||||
|---|---|---|---|---|---|---|
| Est. Long Term Growth Rate: |
Net Profit () |
EPS () |
DPS () |
Net Profit () |
EPS () |
DPS () |
| Consensus Estimate | ||||||
| 1m Change | ||||||
| 3m Change | ||||||
Cochlear Ltd is an Australia-based company that provides implantable hearing solutions. The Company provides bone conduction implants for people with conductive hearing loss, mixed hearing loss and single-sided deafness. Its segments include Americas, EMEA and Asia Pacific. Americas includes the United States, Canada and Latin America. EMEA includes Europe, Middle East and Africa. Asia Pacific includes Australasia and Asia. Its implantable hearing solution portfolio includes Cochlear implants, such as Cochlear Nucleus Profile Plus with Slim Modiolar Electrode (CI632), Cochlear Nucleus Kanso Sound Processor (CP950), Cochlear Nucleus 7 Sound Processor (CP1000) and Cochlear Nucleus smart application and bone conduction implants, such as Cochlear Baha 5, Baha 5 Power and Baha 5 SuperPower, Cochlear Baha SoundArc, Cochlear Baha Smart App and Cochlear Carina System.
| Last Annual | June 30th, 2020 |
| Last Interim | June 30th, 2020 |
| Incorporated | June 8, 1983 |
| Public Since | December 4, 1995 |
| No. of Shareholders: | 42,531 |
| No. of Employees: | 4,000 |
| Sector | Healthcare |
| Industry | Healthcare Equipment & Supplies |
| Index | S&P/ASX 50 , S&P/ASX All Ordinaries , S&P/ASX 100 , S&P/ASX 200 , S&P/ASX 300 , FTSE Developed Asia Pacific , FTSE Developed Asia Pacific Ex Japan , |
| Exchange | Australian Stock Exchange - SEATS |
| Shares in Issue | 65,687,402 |
| Free Float | (0.0%) |
| Eligible for |
ISAs
SIPPs
|
As of 5:10am, shares in Cochlear are trading at A$195.65, giving the company a market capitalisation of ÂŁ7.12bn. This share price information is delayed by 15 minutes.
Shares in Cochlear are currently trading at A$195.65 and the price has moved by -20.56% over the past 365 days. In terms of relative price strength - which takes into account the overall market trend - the Cochlear price has moved by -17.57% over the past year.
Of the analysts with advisory recommendations for Cochlear, there are there are currently 1 "buy" , 4 "hold" and 3 "sell" recommendations. The overall consensus recommendation for Cochlear is Sell. You can view the full broker recommendation list by unlocking its StockReport.
Cochlear is scheduled to issue upcoming financial results on the following dates:
The Cochlear dividend yield is 0.84% based on the trailing twelve month period.
Last year, Cochlear paid a total dividend of 1.6, and it currently has a trailing dividend yield of 0.84%. Looking ahead, Cochlear has not announced an ex-dividend date yet.
Cochlear has yet to annouce their ex-dividend date. The historic dividend yield on Cochlear shares is currently 0.84%.
To buy shares in Cochlear you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
Shares in Cochlear are currently trading at A$195.65, giving the company a market capitalisation of ÂŁ7.12bn.
Here are the trading details for Cochlear:
Based on an overall assessment of its quality, value and momentum, Cochlear is currently classified as a Falling Star. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Shares in Cochlear are currently priced at A$195.65. At that level they are trading at 5.38% discount to the analyst consensus target price of 0.00.
Analysts covering Cochlear currently have a consensus Earnings Per Share (EPS) forecast of 3.37 for the next financial year.
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Cochlear. Over the past six months, the relative strength of its shares against the market has been -13.14%. At the current price of A$195.65, shares in Cochlear are trading at -3.93% against their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Cochlear PE ratio based on its reported earnings over the past 12 months is 34.52. The shares are currently trading at A$195.65.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Cochlear's management team is headed by:
Here are the top five shareholders of Cochlear based on the size of their shareholding:
